Compare KMDA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | EOLS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Israel | United States |
| Employees | 374 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.3M | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | KMDA | EOLS |
|---|---|---|
| Price | $6.97 | $6.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.00 | ★ $21.25 |
| AVG Volume (30 Days) | 66.9K | ★ 1.8M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 30.41 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | $174,787,000.00 | ★ $285,823,000.00 |
| Revenue This Year | $14.49 | $13.39 |
| Revenue Next Year | $10.12 | $26.85 |
| P/E Ratio | $19.14 | ★ N/A |
| Revenue Growth | 10.36 | ★ 15.10 |
| 52 Week Low | $5.54 | $5.71 |
| 52 Week High | $9.16 | $17.12 |
| Indicator | KMDA | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 45.09 |
| Support Level | $6.70 | $6.53 |
| Resistance Level | $6.83 | $7.15 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 47.65 | 6.17 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.